Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vulpes Corp is a materials science and biotechnology company based in St. Louis, Missouri, that specializes in the development of proprietary carbon-based materials for targeted delivery applications. The company's core technology platform utilizes a "molecular foundry" to create customized carbon-based nanostructures designed to encapsulate and deliver active ingredients with high precision. While initially focused on agricultural applications to improve the delivery of nutrients and crop protection agents, Vulpes has expanded into the life sciences sector to address challenges in drug delivery, bio-imaging, and diagnostics. Their platform aims to enhance the bioavailability and safety profiles of various therapeutic payloads, including small molecules and biologics, by enabling site-specific release and reducing off-target effects. The company is currently in the pre-clinical stage for its healthcare applications and collaborates with academic and industry partners to validate its delivery systems.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vulpes Corp.